Search

Search Results

• PO:25:085 | Anti-MDA5 antibody syndrome, a life-threatening condition for rheumatologist and pulmonologist A case series Francesca Cozzini^1|2, Cecilia Burattini¹, Elena Bravi¹, Chiara Nani¹, Eugenio Arrigoni¹, Fabia Cavallotti¹, Ilaria Platè¹, Marco Sebastiani^1|3 | ¹Ospedale Guglielmo da Saliceto Piacenza, Italy; ²Università degli studi di Modena e Reggio Emilia, Italy; ³Università degli Studi di Parma, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2354

  41

• B-cell depletion and primary Sjögren’s syndrome: is there a role for rituximab?

  F. Atzeni, P. Sarzi-Puttini

  87-88

  https://doi.org/10.4081/reumatismo.2010.87

  1341

  PDF: 727

• CO:10:3 | Clinical response to JAK inhibitors or non-TNFi-targeted biologicals according to synovial tissue characteristics in patients with difficult-to-treat rheumatoid arthritis Mariangela Salvato¹, Alessandro Giollo¹, Francesca Frizzera¹, Kiren Khalid¹, Lorenzo Di Luozzo¹, Maria Capita¹, Marianna Tamussin¹, Carlo Garaffoni², Marny Fedrigo³, Annalisa Angelini³, Ettore Silvagni², Andrea Doria¹. | ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova; ²Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna; ³Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.1992

  151

• PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo¹, Corrado Campochiaro², Gábor Kumánovics³, Christina Bergmann⁴, Elisabetta Zanatta⁵, David Launay⁶, Serena Guiducci⁷, Mickael Martin⁸, Carolina De Souza Müller⁹, Carlomaurizio Montecucco¹⁰, Luc Mouthon¹¹, Gabriella Szucs¹², Kastriot Kastrati¹³, Marie-Elise Truchetet¹⁴, Madelon Vonk¹⁵, Francesco Del Galdo¹⁶, Marco Matucci-Cerinic², Gianluca Moroncini¹, Yannick Allanore¹⁷. | ¹Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; ²Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; ³University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; ⁴University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; ⁵Padova University Hospital, Rheumatology Unit, Padova, Italy; ⁶Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; ⁷University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; ⁸Poitiers University Hospital, Department of Internal Medicine Poitiers France; ⁹Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; ¹⁰Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; ¹¹Hôpital Cochin, Department of Internal Medicine, Paris, France; ¹²University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; ¹³Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; ¹⁴CHU de Bordeaux, Rheumatology department, Bordeaux, France; ¹⁵Radboudumc, Department of Rheumatology Nijmegen The Netherlands; ¹⁶Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; ¹⁷Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2077

  154

• PO:18:264 | Anifrolumab in Systemic Lupus Erythematosus: Bridging Clinical Trial Data with Real-World Evidence Giulia Cassone², Filippo Santoro¹, Caterina Vacchi², Dilia Giuggioli², Chiara Cabassi¹ | ¹UOC Reumatologia, AOU Policlinico di Modena, Università degli studi di Modena e Reggio Emilia Modena e Reggio Emilia, Italy; ²UOC Reumatologia, AOU Policlinico di Modena Modena, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2337

  71

• PO:25:079 | Anifrolumab in refractory dermatomyositis: a case report Chiara Calabrese¹, Corrado Campochiaro^1|2, Giacomo De Luca ^1|2, Veronica Batani¹, Marco Matucci-Cerinic^1|2, Lorenzo Dagna ^1|2 | ¹Dipartimento di Reumatologia e Scienze Mediche, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO Milano; ²Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e Trapianti, Milano, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2190

  150

• PO:24:063 | Interstitial lung disease in idiopathic inflammatory myopathy patients: efficacy and safety of nintedanib Giulia Buonsante^1|2|3, Giacomo De Luca^1|2|3, Veronica Batani^1|2, Lorenzo Dagna^1|2|3, Marco Matucci-Cerinic^1|2|3, Corrado Campochiaro^1|2|3 | ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital Milano, Italy; ²Inflammation, Fibrosis and aging Initiative INFLAGE, IRCCS San Raffaele Hospital Milano, Italy; ³Vita-Salute San Raffaele University, Milano, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2350

  36
• 

  Concurrent herpetic hypertensive anterior uveitis and cytomegalovirus retinitis in a non-HIV patient with melanoma differentiation-associated gene-5 dermatomyositis: intravenous immunoglobulin comes to the rescue

  T Aizan Izzati Binti T Mohd Yatim, Chiew Gek Khor, Eu Ping Poh

  21-04-2026

  https://doi.org/10.4081/reumatismo.2026.1826

  176

  PDF: 33